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Abstract Pituitary adenylate cyclase-activating polypep-
tide (PACAP) has been shown to increase the histamine
release from gastric enterochromaffin-like (ECL) cells and
promote gastric acid secretion in rats. In contrast, in mice,
PACAP has been demonstrated to induce a decrease of
gastric acid secretion, an effect presumably due to somato-
statin release. To more clearly define the role of PACAP in
the regulation of gastric acid output, a knockout mouse
model for the PACAP-specific receptor PAC1 was applied
in this study. Measurements of the basal and stimulated
gastric acid secretion and morphological studies on the
gastric mucosa were performed in both wild-type and
PAC1-deficient mice. Compared with the wild-type mice,
the PAC1-deficient mice showed a nearly threefold higher
basal gastric acid output, increased gastric mucosa thick-
ness and glands height, and proportional increases in
parietal and total cell counts in the gastric mucosa. The
PAC1-deficient mice also showed a trend of increased
plasma gastrin levels and gastrin gene expression in the
gastric mucosa. This study indicates that the expression of
PAC1 is clearly important for maintaining the homeostasis
of gastric acid secretion. Loss of PACAP receptor during
development may lead to a compensatory mechanism
regulating gastric acid secretion.
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Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP)
belongs to the family of peptides that includes vasoactive
intestinal polypeptide (VIP), secretin, and glucagon (Miyata
et al. 1989). PACAP functions through its type 1 receptor
(PAC1) and two VIP receptors, VPAC1and VPAC2.
However, the PAC1 receptor is PACAP-specific, exhibiting
1,000-fold greater affinity for PACAP than for VIP
(Fradinger et al. 2005). PACAP and PAC1 immunoreac-
tivities show a similar distribution pattern in the gastro-
intestinal tract, mainly in the myenteric ganglia and the nerve
fibers in muscle layers (Sundler et al. 1992; Miampamba et
al. 2002). While PACAP has also been shown in the
gastrointestinal mucosa (Miampamba et al. 2002), PAC1
has been reported to be expressed on isolated gastric
enterochromaffin-like (ECL) cells (Oh et al. 2005). All
these suggest that PACAP plays an important role in the
regulation of gastric acid secretion and gastrointestinal
motor function.
We and other authors have described that exogenously
administered PACAP stimulates gastric acid secretion in
rats (Zeng et al. 1998, 1999; Sandvik et al. 2001). The
activation of PAC1 and its induction of ECL histamine
release, in addition to the subsequent downstream parietal
cell functioning, have been examined in vitro (Zeng et al.
1999). Histamine exocytosis in ECL cells is induced by
extracellular Ca
2+ entry into the ECL cell, rather than IP3-
induced mobilization of intracellular Ca
2+ (Lindström et al.
2001). Furthermore, PACAP-induced histamine secretion
can be blocked by nifedipine, leading investigators to
propose that the binding of PACAP to PAC1 regulates
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2+ channels by the induced secondary messenger cAMP
in ECL cells (Lindström et al. 2001).
However, in murine models, the opposite effect has been
shown, with PACAP inducing a reduction of gastric acid
secretion, that it is presumed to be secondary to PACAP-
mediated somatostatin release through another PACAP
receptor, VPAC1, on gastric D cells. This effect can be
unmasked by immunoneutralization of somatostatin or in
the presence of a SSTR2 antagonist in wild-type mice or in
a SSTR2 gene knockout mouse model (Piqueras et al.
2004). The precise role of PACAP and its receptors in the
regulation of gastric acid secretion has yet to be better
defined. A PAC1-deficient mouse model is currently
available (Jamen et al. 2000), and here, we have performed
physiological and morphological studies on this mouse
model to elucidate the in vivo effects of PAC1 deficiency
on the gastric acid secretion.
Materials and Methods
Animals
Mice deficient in PAC1 receptor were generated as previ-
ously described (Jamen et al. 2000). The mice were received
as F1 and further backcrossed on the C57BL/6 background
for ten generations. Adult male mice aged 12–24 weeks
were used in experimentation, and the wild-type (C57BL/6)
counterparts served as controls to the PAC1-deficient mice.
Mice were fasted for food for 16–18 h until the beginning
of the experiments. All the procedures involving animals
were conducted in accordance with international standards
on animal welfare and approved by the Animal Research
Committee of the Veterans Affairs Greater Los Angeles
Healthcare System.
Assay for Gastric Acid Secretion
The assay was performed in urethane-anesthetized mice,
as previously described (Zeng et al. 1998). Fasted wild-
type and PAC1-deficient mice aged 12–24 weeks were
anesthetized with urethane (1.25 g/kg i.p.). The abdomen
was opened and the pylorus was ligated by 3-0 silk sutures
(Ethicon, Somerville, NJ). A small incision was made in the
foregut, and a double-lumen gastric cannula was inserted
into the gastric lumen. The incision was then closed on the
cannula by 3-0 silk sutures. A catheter [30-gauge needle
inserted into polyethylene E-10 tubing (Baxter, Irvine, CA)]
was placed into the saphenous vein for constant intravenous
infusion of normal saline and administration of test
substances (0.1 ml/h). Gastric acid secretion was deter-
mined by continuous intragastric perfusion with warm
saline (pH 7.0, 0.3 ml/min). Harvard syringe pumps
(Harvard Apparatus, Holliston, MA) were applied for the
above intravenous infusion and gastric perfusion. A 30-min
period was allowed for stabilization and, thereafter, the
effluents were collected at 10-min intervals and back
titrated to pH 7.0 (0.001 N NaOH) with an automatic
titrator (Radiometer Copenhagen, Westlake, OH). Rat
gastrin I (Bachem, Torrance, CA) and histamine (Sigma-
Aldrich, St Louis, MO) were dissolved in sterile water and
administered at the indicated time points and doses in each
experiment.
Measurement of Plasma Gastrin Levels
Plasma was obtained from wild-type and PAC1-deficient
mice aged 12–24 weeks, and the circulating gastrin levels
were determined by radioimmunoassay (RIA) using a
commercial Euria-Gastrin kit (Euro Diagnostica, Maelmo,
Sweden; courtesy of Dr. Stephen Wank, NIDDK and NIH).
Assay for Marker Gene Expression in Gastric Mucosa
qPCR was performed to determine the expression level of
marker genes in mouse gastric mucosa, as previously
described(Lambrechtetal.2005). Freshly resected stomachs
from fasted mice aged 16 weeks were opened, and the
oxyntic mucosa was scraped off using the sharp edge of a
slide. The fragments were homogenized in 2 ml of
RNAlater (Qiagen, Valencia, CA) on ice and then filtered
through a nylon sieve. Total RNA from the homogenate was
isolated using the RNeasy protect mini kit (Qiagen), and
0.5 μg of total RNAwas applied for the reverse transcriptase
(RT) reaction using the Superscript first-strand synthesis kit
(Invitrogen, Carlsbad, CA). Two micrograms of RT product
was then added in a reaction with SYBR premix Taq
(Takara Bio, Shiga, Japan) for qPCR, which was performed
on the DNA Engine Opticon 2 system (MJ Research,
Waltham, MA). The cycle of threshold, C(T), was deter-
mined as the fluorescent signal of 1 standard deviation over
background. The efficiency of each primer pair was
measured by amplification of the known amount of cDNA
starting material (10 pg–10 ng). Target primer pair ampli-
fications were compared with the reference primer pair
(beta-actin) amplification in the same experiment for each
RT product tested. All reactions were carried out in
duplicate. The relative expression ratio of the target gene
compared with the reference gene was calculated according
to the Pfaffl's formula:
Ratio ¼ð EfficiencytargetÞ
ΔCðTÞtargetðsample controlÞ
=ðEfficiencyreferenceÞ
ΔCðTÞreferenceðsample controlÞ:
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mouse gastric mucosa are listed as follows:
VMAT-2: S-CTCGCGCTGCTGCTAGACAACAT;
AS-GGCGATCAGCAGGAAGGCATAGC
HDC: S-CTTTCTCATCCCGGCTACTATCCA; AS-
ACCGCGTTGTCTTCCTCCTGT
Somatostatin: S-GTCCTGGCTTTGGGCGGTGTC;
AS-GAGATATGGGGTTTGGGGGAGAGG
Pepsinogen: S-TCCGGATTTCTTGCCTATGACACT;
AS-ACTGGCTGGCACTGGGTAGGTAAC
Na-K-ATPase: S-CGCCCTCACACCCCCTCCC
ACTAC; AS-CCACCAGATCCCCGACGACGACAT
Kcnq1: S-GCCCGGCCCACACTAACTGC; AS-GG
TGCCCAAGCCCAAGGAAC
H-K-ATPase: S-GACCGGACGTGTATGGGGAAA
GAG; AS-GGGTTGCTGTAGTGGGGCTGTGCT
Gastrin: S-GGGAGCGCCACAACAGC; AS-GCGG
CGGCCAAAGTCCA
CCK-B receptor: S-CGCCGCGGGAGCAGGTG; AS-
ATGGCCGCGAGATTTAGAGTGGAC
Somatostatin receptor-2: S-CGACCCCGGACAGCCA
AGATGAT; AS-ATGGCCACAGACACGGAA
GAGACG
Beta-actin: S-CTAAGGCCAACCGTGAAAAGA
TGA; AS-ACCGCTCGTTGCCAATAGTGATG
Immunohistochemistry and Morphological Measurements
Stomachs were collected from fasted wild-type and PAC1-
deficient male mice aged 12–16 weeks. Tissues were fixed
overnight in 4% paraformaldehyde, embedded in paraffin,
and 5-μm sections were stained with hematoxylin and eosin
(H&E) or mouse monoclonal H-K-ATPase antibodies 1:500
(gift of Dr. George Sachs, UCLA), rabbit polyclonal
chromogranin A antibodies 1:2,000 (Incstar, Stillwater,
MN) or mouse monoclonal somatostatin antibodies 1:100
(CURE Antibody Core, Los Angeles). Immunohisto-
chemistry was performed using a peroxidase method.
Rehydrated tissue sections were incubated for 18 h at 4°C
with the respective primary antibodies, then washed and
incubated for 1 h at room temperature with biotinylated
goat antirabbit or antimouse antibodies 1:500 (Vector
Laboratories, Burlingame, CA), incubated 1 h at room
temperature with avidin-biotinylated horseradish peroxidase
complex (Vectastain ABC Elite Kit, Vector Laboratories),
and then developed in 0.25 mg/ml 3,3′-diaminobenzidine
tetrahydrochloride (DAB). After washing, sections were
counterstained with hematoxylin.
Sections were viewed and photographed under micro-
scope with the ×10 objective. Sections stained with H&E
were used to measure the mucosal thickness, gland height,
and pit height. Six to ten separate measurements were made
per animal. Sections stained with H-K-ATPase antibody
were used to count the parietal cells (stained) and total cells
per gland. Cells of six to ten well-oriented glands per
animal were counted manually. Chromogranin A-positive
cells and somatostatin-positive cells were counted per
millimeter of horizontal length of tissue, using five to eight
separate fields per animal with total length of 3–8 mm per
animal.
Statistical Analysis
Group comparisons were analyzed by using the Student's
t test. Statistical significance was set at p<0.05.
Results
PAC1 Deficiency Results in Basal Gastric
Acid Hypersecretion
Since PAC1 is the specific receptor for PACAP and the only
receptor expressed on ECL cells in gastric mucosa, we were
interested in understanding the effects of PAC1 deficiency on
the basal gastric acid secretion. After an overnight fast, mice
wereanesthetizedtoperformgastricacidsecretionassaywith
constant intravenous infusion of saline. PAC1-deficient mice
were noted to have an elevated basal gastric acid output over
theentireobservationperiodof110min(Fig.1). The average
basal gastric acid output observed in PAC1 knockout mice
was 0.29±0.05 μmol/10 min, whereas for the wild-type
mice, the average basal acid output was 0.10±0.01 μmol/
10 min. This translated to an approximately threefold higher
basal stimulation in PAC1-deficient mice, compared with
wild-type mice (p<0.001).
To further understand the profile of gastric acid secretion
in PAC1-deficient mice, we next investigated the histamine
stimulatory pathway (Fig. 2). After 30 min of stabilization
with warm saline, the mice were constantly infused with
histamine at the dosage of 1 mg/kg/h. The resulting gastric
Figure 1 Measurements of basal gastric acid output in PAC1-
deficient and wild-type mice fasted overnight, anesthetized, and
constantly infused with warm saline. Data shown are the average
values ± standard error of the mean (SEM; n=5 mice per group)
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histamine infusion in both PAC1-deficient and wild-type
mice and reached the peak at the end of the 2-h observation
period, sevenfold in PAC1-deficient mice and tenfold in
wild-type mice, compared with their basal acid output.
Compared with the wild-type mice, the PAC1-deficient
mice had higher acid secretion levels at the end of the
observation period (p<0.01). The results indicate that the
PAC1-deficient mice have an intact histamine stimulatory
pathway in gastric acid secretion.
The gastrin stimulatory pathway was also explored with
exogenous gastrin administration in both PAC1-deficient
and wild-type mice (Fig. 3). After 30 min of stabilization,
the mice were constantly infused with rat gastrin I peptide.
At the dosage of 100 μg/kg/h, the acid output was increased
twofold in the wild-type mice, while no stimulatory effect
was shown in the PAC1-deficient mice. However, at a
higher dosage of 500 μg/kg/h of rat gastrin I peptide in both
PAC1-deficient and wild-type mice, the gastric acid output
was increased to a significant level (p<0.05), which was
2.3-fold in PAC1-deficient mice and sevenfold in wild-type
mice, compared with their basal acid output. These results
indicate that, although in the PAC1-deficient mice the
gastrin stimulatory pathway is functional, there is a higher
threshold to the effects of exogenous gastrin.
PAC1 Deficiency Results in Hypertrophic Gastric Mucosa
To determine whether differences in tissue histology could
explain the physiological responses described above,
stomach tissues from fasted PAC1-deficient and wild-type
mice were sectioned for H&E staining (Fig. 4a). PAC1-
deficient mice showed a greater mucosal thickness (0.49±
0.12 mm) compared with wild-type mice (0.33±0.06 mm,
p<0.01; Fig. 4b). This different mucosal thickness in the
two groups of mice was ascribed to the greater gland height
inPAC1-deficientmice(0.43±0.12mm)comparedwithwild-
type mice (0.27±0.06 mm, p<0.01; Fig. 4c). No significant
difference was found between the two groups of mice with
regards to the pit height (Fig. 4d).
To assess the effects of PAC1 deficiency on the cellular
components of the gastric glands, we performed immuno-
histochemical staining using anti-H-K-ATPase antibodies.
The stained sections (in Fig. 5a) showed an increased
number of parietal cells per gland in PAC1-deficient mice
(27.5±8.4) compared with wild-type mice (16.1±3.4, p<
0.01; Fig. 5b). The total cellular composition (Fig. 5c) per
gland in PAC1-deficient mice (56.9±13.6) was also in-
creased, compared with the wild-type mice gland (32.8±7.3,
p<0.01). These results indicate that the parietal cells mass is
increased in the gastric mucosa of PAC1-deficient mice.
PAC1-Deficient Mice Show a Trend of Increase in Plasma
Gastrin Level and Gastrin Gene Expression
To determine whether there is a difference in the circulating
gastrin levels between PAC1-deficient and wild-type mice,
fasting plasma gastrin levels were measured by RIA
(Fig. 6). PAC1-deficient mice had an average circulating
gastrin level of 115±50 pmol/L, while wild-type mice had
an average level of 76±35 pmol/L, indicating that PAC1-
deficient mice have 34% higher circulating gastrin levels,
compared with the wild-type mice (p=0.035). The observed
higher threshold to the effects of exogenous gastrin in
PAC1-deficient mice might result from the relatively higher
levels of endogenous gastrin observed in this model.
In order to correlate the above findings, qPCR was
performed to measure the expression of specific cell type
marker genes (gastrin, somatostatin, somatostatin receptor
2, histidine decarboxylase, vesicular monoamine transporter
2, cholecystokinin beta receptor, H-K-ATPase, Kcnq1,
pepsinogen, ghrelin, and Na-K-ATPase in gastric mucosa).
The results (in Fig. 7) show a gastrin mRNA level in the
gastric mucosa approximately fivefold higher in PAC1-
deficient mice compared with wild-type mice (p=0.01). A
lower change in gene expression (ratio <2) was found in the
Figure 2 Measurements of histamine-stimulated gastric acid output
in PAC1-deficient and wild-type mice. Histamine was infused 30 min
post-stabilization with saline. Data shown are the average values ±
SEM (n=3 mice per group)
Figure 3 Measurements of gastrin-stimulated gastric acid output in
PAC1-deficient and wild-type mice. Rat gastrin I was infused 30 min
post-stabilization with saline. Data shown are the average values ±
SEM (n=4 mice per group)
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such as ECL, D, and X/A cells, as shown in Fig. 7.N o
variation was found in the expression of the beta-actin gene
in gastric mucosa between wild-type and PAC1-deficient
mice (data not shown).
PAC1 Deficiency Does Not Result in Changein D Cell Counts
To determine whether a difference in the numbers of D cells
and other neuroendocrine cells exists between PAC1-
deficient and wild-type mice, to account for the noted
physiological changes, immunohistochemical analysis with
antisomatostatin (D cells) and antichromogranin A (neuro-
endocrine cells) antibodies was performed on gastric corpus
sections. A similar numbers of D cells (Fig. 8a, b) were
found in PAC1-deficient (13.6±6.2/mm) and wild-type
mice (14.7±9.2/mm, p>0.05), as well as total neuroendo-
crine cells numbers (Fig. 8c, d) in PAC1-deficient (36.3±
23.2/mm) and wild-type mice (45.1±22.7/mm, p>0.05).
These results are consistent with the qPCR data previously
shown in this paper.
Discussion
Historically, studies describing the effects of exogenous
PACAP administration on gastric acid secretion have given
very different and opposite results (Zeng et al. 1999; Sandvik
et al. 2001;P i q u e r a se ta l .2004). These different data are
due in part to the ability of PACAP to bind to both PAC1
and VPACs receptors, which may be species-related. The
precise role of PACAP in mediating gastric acid output has
yet to be completely determined. The data shown here
characterize, for the first time, the effects of PAC1 deletion
on gastric acid physiology and gastric histology. In the PAC1-
deficient mouse model, we explored the consequence of the
effects of gastrin and histamine on gastric acid physiology.
Gastrin is considered upstream of the effect because it is
generallyreleasedbytheantralGcellsinresponsetoaprotein
dietthrougha yetunknownreceptor.AntralGcellstimulation
results in gastrin release. Gastrin in turn stimulates the CCK2
receptor present on the ECL cell of the stomach to in turn
release histamine. The mechanism regulating this process is
an intracellular Ca++ pathway (Zeng et al. 1999). The
elevated basal gastric acid output, observed in the PAC1-
deficient mice, most likely results from a downward shift in
the neuroendocrine axis that regulates acid output, leading to
enhanced parietal cell number and function. The PAC1-
deficient mice in this study had an increased mucosal
thickness and gland height, due in part to increased parietal
cell number, compared with the wild-type mice.
In the PAC1-deficient mice, the observed hypertrophy of
the gastric mucosa could be partially due to the relatively
higher gastrin levels observed. Gastrin is an important
Figure 4 H&E staining and
morphological measurements
of gastric mucosa in PAC1-
deficient and wild-type mice.
a H&E staining, b mucosa
thickness (p<0.01), c gland
height (p<0.01), d pit height.
Data shown are the average
values ± SEM (n=3 mice per
group)
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mucosal cells. In a gastrin-deficient mouse model, de-
creased numbers of parietal and ECL cells were observed
(Koh et al. 1997). Since the advent of potent gastric acid
inhibitory agents, such as the proton pump inhibitors, that
block the activity of H-K-ATPase, there has been a concern
regarding their potential risk for inducing ECL cell
hyperplasia and gastric carcinoid tumor genesis. The
induction of these tumors is thought to be due to hyper-
gastrinemia caused by proton pump inhibitors. In our
PAC1-deficient mice, we did not identify the development
of gastric carcinoid tumors or ECLomas (Lieu et al. 2006).
PACAP has demonstrated antisecretory effects through
the release of somatostatin from D cells in a mouse model;
however, a rapid change in the concentration of histamine
or gastric acid induced by stimulants usually works as a
trigger for somatostatin release (Piqueras et al. 2004). In
PAC1-deficient mice, basal gastric acid output has been
rebalanced to a new stable level, a situation in which the
physiological status of D cells may not be altered. This is
consistent with the lack of any significant difference found
in this study in D cell counts and in somatostatin and
somatostatin receptor 2 gene expression in the gastric
mucosa of both PAC1-deficient and wild-type mice.
PACAP has been shown to stimulate the proliferation of
ECL cells (Läuffer et al. 1999). We previously demonstrated
by cytofluorimetric analysis and RT-PCR that only PAC1,
but not VPAC1, is expressed on ECL cells (Oh et al. 2005),
leading to the conclusion that the PAC1 receptor is the sole
pathway for PACAP signaling in these cells. We would,
therefore, expect that the absence of PACAP stimulation in
PAC1-deficient mice could have a significant effect on ECL
cell differentiation. However, the levels of expression of the
ECL-specific HDC and VMAT2 genes in the gastric
mucosa were similar in both PAC1-deficient and wild-
type mice. In addition, no difference was seen between the
two groups of mice in the number of chromogranin A-
positive cells, of which the ECL cells constitute the larger
Figure 6 Levels of fasting plasma gastrin were measured in PAC1-
deficient (p=0.035) and wild-type mice by RIA. Data shown are the
average values ± SEM (n=10 mice per group)
Figure 5 Immunohistochemistry
and measurements of gastric
gland cell components in PAC1-
deficient and wild-type mice.
a Immunohistochemical staining
with anti-H-K-ATPase antibody,
b parietal cell counts (p<0.01),
c total gland cell counts
(p<0.01). Data shown are the
average values ± SEM (n=3
mice per group)
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cells, this phenomenon might be due to the relative increase
of gastrin level in PAC1-deficient mice that could com-
pensate for the lack of PACAP (McLaughlin et al. 2004).
Direct staining of antral G cells, staining of ECL cells with
anti-HDC and anti-VMAT2 antibodies, as well as studies
on the isolated G and ECL cell population, which we are
working on, will further increase our understanding of the
physiological changes in G and ECL cells due to PAC1
deficiency.
Figure 7 Marker genes expres-
sion of gastrin, somatostatin,
somatostatin receptor 2 (SSTR2),
histidine decarboxylase,
vesicular monoamine transporter
2 (VMAT2), cholecystokinin
beta receptor (CCKBR), H-K-
ATPase, Kcnq1, pepsinogen,
ghrelin, and Na-K-ATPase were
analyzed by qPCR in PAC1-
deficient and wild-type mice
gastric mucosa. Data shown are
the average values ± SEM
(n=4 mice per group). Statistical
analysis was performed using
Student's t test (paired samples).
Error bars represent the SEM
Figure 8 Immunohistochemistry
and neuroendocrinecellcounts in
PAC1-deficient and wild-type
mice. a Immunohistochemical
staining with antisomatostatin
antibody, b D cell counts,
c immunohistochemical staining
with antichromogranin A
antibody, d chromogranin
A-positive cell counts. Data
shown are the average values ±
SEM (n=3 mice per group)
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Urethane has been reported to inhibit acid secretion by a
mechanism of stimulating somatostatin release, associated
with a reduction in low basal acid secretion in rodent models.
However, in our current study, despite this potential for
reducing gastric acid secretion by urethane, we have
observed, in the PAC1-deficient mice, a significant increase
in gastric acid secretion, compared with wild-type mice with
normal expression of PAC1. Under urethane anesthesia,
PAC1-deficient mice showed intact responses to secreta-
gogues. We considered other anesthetics such as isoflurane
and halothane. However, isoflurane has been shown to have a
stimulatory effect on acid secretion in rats (Kaunitz, unpub-
lished observations). Halothane has been reported to increase
the gastric pH in humans (Schurizek et al. 1989).
In our knockout mouse model,relativelyincreased gastrin
levels may have contributed to elevated gastric acid output,
by exerting a direct stimulatory effect on gastric parietal cells
via gastrin receptor. In a previously described SSTR2
knockout mouse model, the observed morphological and
functional changes signaled a shift in ECL cell regulation:
from a paracrine (somatostatin)-dependent pathway to a
possible hypothesized neurocrine-dependent pathway (Zhao
etal.2008).Here,wesuggestasimilarshiftinthestimulatory
regulation of the parietal cell by the gastrin–ECL cell axis
with an enhancement of the direct gastrin effects. The rat
gastrin I peptide used in our studies has been showed to be
less potent than pentagastrin in the stimulation of gastric acid
secretion as previously reported (Piqueras et al. 2004). We
have already developed and studied VIP-deficient mice in
which we have shown profound motility changes through-
out their intestine (unpubl i s h e dd a t a ) ,l e a d i n gt ot h e
development of intestinal ileus and a form of Hirschsprung's
disease (Lelievre et al. 2007). Characterization of the effects
of VIP hormone deletion on the development of gastric acid
secretionwould be also very interesting to study. The specific
role of PACAP hormone deficiency was not examined in
our PAC1 receptor knockout mice. However, this model
would be of significant importance to further our under-
standing of the direct role of the hormone PACAP in
regulating gastric acid secretion. With the recent develop-
ment by several groups of a PACAP
−/− mice, this pathway
can be later explored.
Taken as a whole, our findings suggest that there might
be a remodeling of the neuroendocrine mechanisms that
regulate gastric acid output in PAC1-deficient mice. Loss of
a stimulatory pathway via PAC1 leads to physiological
compensation and to an elevated basal acid output that is in
part mediated by a release of gastrin or other unknown
mechanisms.
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